glp-1 agonist gastroparesis New data links agonists for weight loss with higher risk for pancreatitis, GI events Frontiers | GLP-1/GIP dual agonist
Description
Our narrative review discussed the CV benefits of GLP-1 RAs in terms of controlling CV risk factors and improving CV outcomes in diabetic and nondiabetic patients regardless of their CV history, and the CV perspectives related to their use in clinical practice
Takagi H, Umemoto T, Group A
This milestone marks the initiation of the first Phase 3 clinical trial of Bofanglutide injection worldwide for the treatment of T2DM
Strokes are one of the main causes of adult disability
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY)
Meier 2012)
